10/17
07:00 am
antx
AN2 Therapeutics Receives Continuation Grant to Discover Novel Boron Based Therapies for Tuberculosis (caused by Mycobacterium tuberculosis) and Malaria
Medium
Report
AN2 Therapeutics Receives Continuation Grant to Discover Novel Boron Based Therapies for Tuberculosis (caused by Mycobacterium tuberculosis) and Malaria
9/11
05:34 pm
antx
Nontuberculous Mycobacterial Infection Market to Exhibit Growth at a CAGR of 13.4% in the US by 2034 | DelveInsight [Yahoo! Finance]
Neutral
Report
Nontuberculous Mycobacterial Infection Market to Exhibit Growth at a CAGR of 13.4% in the US by 2034 | DelveInsight [Yahoo! Finance]
8/28
04:00 pm
antx
AN2 Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Neutral
Report
AN2 Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
8/19
11:39 am
antx
AN2 Therapeutics (ANTX) Plunges 66% in a Month: Here's Why [Yahoo! Finance]
Medium
Report
AN2 Therapeutics (ANTX) Plunges 66% in a Month: Here's Why [Yahoo! Finance]
8/16
07:14 am
antx
AN2 Therapeutics Adopts Limited Duration Stockholder Rights Plan [Yahoo! Finance]
Medium
Report
AN2 Therapeutics Adopts Limited Duration Stockholder Rights Plan [Yahoo! Finance]
8/16
07:00 am
antx
AN2 Therapeutics Adopts Limited Duration Stockholder Rights Plan
Medium
Report
AN2 Therapeutics Adopts Limited Duration Stockholder Rights Plan
8/13
04:19 pm
antx
AN2 Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business and Scientific Highlights [Yahoo! Finance]
Low
Report
AN2 Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business and Scientific Highlights [Yahoo! Finance]
8/13
04:01 pm
antx
AN2 Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business and Scientific Highlights
Medium
Report
AN2 Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business and Scientific Highlights
8/9
12:34 pm
antx
Lung Disease Focused AN2 Therapeutics' Lackluster Data Prompts To Stop Phase 3 Study Of Lung Infection Candidate, Halves Workforce [Yahoo! Finance]
Medium
Report
Lung Disease Focused AN2 Therapeutics' Lackluster Data Prompts To Stop Phase 3 Study Of Lung Infection Candidate, Halves Workforce [Yahoo! Finance]
8/8
04:30 pm
antx
AN2 Therapeutics Provides Update on EBO-301 Phase 2/3 Study Evaluating Epetraborole for Treatment-Refractory Mycobacterium avium Complex (MAC) Lung Disease
High
Report
AN2 Therapeutics Provides Update on EBO-301 Phase 2/3 Study Evaluating Epetraborole for Treatment-Refractory Mycobacterium avium Complex (MAC) Lung Disease